User profiles for Patrick Giguère
Patrick GiguereAssociate Professor at University of Ottawa Verified email at uottawa.ca Cited by 4390 |
Structure-based discovery of opioid analgesics with reduced side effects
…, H Hübner, XP Huang, MF Sassano, PM Giguère… - Nature, 2016 - nature.com
Morphine is an alkaloid from the opium poppy used to treat pain. The potentially lethal side
effects of morphine and related opioids—which include fatal respiratory depression—are …
effects of morphine and related opioids—which include fatal respiratory depression—are …
PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome
…, K Lansu, JD McCorvy, PM Giguère… - Nature structural & …, 2015 - nature.com
G protein–coupled receptors (GPCRs) are essential mediators of cellular signaling and are
important targets of drug action. Of the approximately 350 nonolfactory human GPCRs, more …
important targets of drug action. Of the approximately 350 nonolfactory human GPCRs, more …
Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets
AJ Kimple, DE Bosch, PM Giguère… - Pharmacological reviews, 2011 - ASPET
Because G-protein coupled receptors (GPCRs) continue to represent excellent targets for
the discovery and development of small-molecule therapeutics, it is posited that additional …
the discovery and development of small-molecule therapeutics, it is posited that additional …
Molecular control of δ-opioid receptor signalling
Opioids represent widely prescribed and abused medications, although their signal transduction
mechanisms are not well understood. Here we present the 1.8 Å high-resolution crystal …
mechanisms are not well understood. Here we present the 1.8 Å high-resolution crystal …
[PDF][PDF] A new DREADD facilitates the multiplexed chemogenetic interrogation of behavior
DREADDs are chemogenetic tools widely used to remotely control cellular signaling, neuronal
activity, and behavior. Here we used a structure-based approach to develop a new G i -…
activity, and behavior. Here we used a structure-based approach to develop a new G i -…
[HTML][HTML] Profiling of basal and ligand-dependent GPCR activities by means of a polyvalent cell-based high-throughput platform
…, G Laroche, JD Freitas, R Wang, PM Giguère - Nature …, 2023 - nature.com
Representing the most attractive and successful druggable receptors of the proteome, GPCRs
regulate a myriad of physiological and pathophysiological functions. Although over half of …
regulate a myriad of physiological and pathophysiological functions. Although over half of …
[PDF][PDF] The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy
…, KW Wen, B Damania, CB Moore, PM Giguère… - Immunity, 2012 - cell.com
The mitochondrial protein MAVS (also known as IPS-1, VISA, and CARDIF) interacts with
RIG-I-like receptors (RLRs) to induce type I interferon (IFN-I). NLRX1 is a mitochondrial …
RIG-I-like receptors (RLRs) to induce type I interferon (IFN-I). NLRX1 is a mitochondrial …
[HTML][HTML] Relative ratios of human seasonal coronavirus antibodies predict the efficiency of cross-neutralization of SARS-CoV-2 spike binding to ACE2
…, SAL Bennett, AM Crawley, PM Giguère… - …, 2021 - thelancet.com
Background Antibodies raised against human seasonal coronaviruses (sCoVs), which are
responsible for the common cold, are known to cross-react with SARS-CoV-2 antigens. This …
responsible for the common cold, are known to cross-react with SARS-CoV-2 antigens. This …
Structural basis for bifunctional peptide recognition at human δ-opioid receptor
G Fenalti, NA Zatsepin, C Betti, P Giguere… - Nature structural & …, 2015 - nature.com
Bifunctional μ- and δ-opioid receptor (OR) ligands are potential therapeutic alternatives, with
diminished side effects, to alkaloid opiate analgesics. We solved the structure of human δ-…
diminished side effects, to alkaloid opiate analgesics. We solved the structure of human δ-…
[HTML][HTML] Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models
…, S Beitari, K Matte, G Laroche, PM Giguère… - Communications …, 2022 - nature.com
Nanobodies offer several potential advantages over mAbs for the control of SARS-CoV-2.
Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern (…
Their ability to access cryptic epitopes conserved across SARS-CoV-2 variants of concern (…